Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript

Advancing differentiated MC4R-based obesity programs into clinical development Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with a primary focus on hypothalamic obesity and Prader-Willi syndrome Oral small-molecule MC4R agonist PL7737 progressing through IND-enabling toxicology studies, with IND submission and clinical trial initiation planned for the first half of 2026 Next-generation selective peptide MC4R agonists d esigned for once-weekly subcutaneous dosing, with IND submission and clinical trial initiation planned for the second half of 2026 Executed sublicensing of MC1R agonist PL9643 in January 2026, sharpening focus on core obesity portfolio while preserving upside Received $3.8 million in upfront consideration Eligible for future milestone payments and royalties Strengthened balance sheet through successful public financing Completed an $18.2 million public offering, including the full exercise of the over-allotment option, on November 12, 2025 Restored NYSE American listing compliance and trading, re-establishing market visibility and liquidity Teleconference and webcast to be held on February 17, 2026 at 11:00 AM ET PRINCETON, N.J., Feb. 17, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced financial results for its fiscal second quarter ended December 31, 2025, and provided a corporate update.

Palatin Technologies, Inc. (OTC:PTN) Q1 2026 Earnings Call November 13, 2025 11:00 AM EST Company Participants Carl Spana - Co-Founder, President, CEO & Director Steve Wills - CFO, COO, Executive VP, Treasurer & Secretary Conference Call Participants Scott Henry - Alliance Global Partners, Research Division Presentation Operator Greetings. Welcome to Palatin's First Quarter Fiscal Year 2026 Operating Results Conference Call.

Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement of NYSE American trading Melanocortin-based therapies for obesity PL7737 IND-enabling toxicology underway; IND submission and clinical trial initiation planned for the first half of 2026 Next-generation selective peptide MC4R agonists d esigned for once-weekly subcutaneous dosing; IND submission and clinical trial initiation planned for mid-2026 Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim for the treatment of retinal diseases in August 2025 Received €2.0M ($2.3M) upfront Achieved €5.5M ($6.5M) research milestone in September 2025 $18.2 million public offering, including full exercise of the over-allotment option, closed on November 12, 2025 Regained compliance with NYSE American listing standards – common stock resumed trading under the symbol "PTN" on November 12, 2025 Teleconference and Webcast to be held on Thursday, November 13, 2025, at 11:00 AM EST PRINCETON, N.J. , Nov. 13, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced financial results for its fiscal first quarter ended September 30, 2025 and provided a corporate update.

Trading of Palatin's common shares resumed trading on NYSE today, November 12, 2025, under the symbol "PTN" PRINCETON, N.J. , Nov. 12, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced underwritten public offering of 2,795,384 shares of its common stock (or pre-funded warrants in lieu thereof), which included the full exercise of the underwriters' option to purchase 364,615 additional shares of common stock (or pre-funded warrants in lieu thereof).